Clinical Trial Update: A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients [NA]

View source ↗

Summary

A completed study evaluating the combination of alisporivir (Debio 025) with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Debio 025 (alisporivir)
• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Debiopharm International SA | Conditions: Chronic Hepatitis C | NA | Status: COMPLETED